Evidence map›Paper›PMID 36124509›Full record

ArticleThe Indian journal of medical research2022

Diethylcarbamazine citrate-fortified salt for lymphatic filariasis elimination in India.

S Sabesan, K Krishnamoorthy, S L Hoti, S Subramanian, A Srividya, Nupur Roy, Tanu Jain, Ashwani Kumar, Manju Rahi

Open access · diamondAbstract read
In one paragraph

Article in The Indian journal of medical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. India's tryst with salt: Dandi march to low sodium salts.The Indian journal of medical research · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

S SabesanVector Control Research Centre, Puducherry, India.
K KrishnamoorthyVector Control Research Centre, Puducherry, India.
S L HotiVector Control Research Centre, Puducherry, India.
S SubramanianVector Control Research Centre, Puducherry, India.
A SrividyaVector Control Research Centre, Puducherry, India.
Nupur RoyNational Centre for Vector-Borne Disease Control, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India, New Delhi, India.
Tanu JainNational Centre for Vector-Borne Disease Control, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India, New Delhi, India.
Ashwani KumarVector Control Research Centre, Puducherry, India.
Manju RahiDivision of Epidemiology & Communicable Diseases, Indian Council of Medical Research, New Delhi, India.
Vector Control Research Centre · INGovernment of India · INIndian Council of Medical Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lymphatic filariasis (LF) is a vector-borne neglected tropical disease, causing permanent disability. The disease is debilitating and widespread, leading to tremendous productivity and economic loss. The Government of India (GOI) prioritized the elimination of LF through the annual mass drug administration (MDA) programme in 2004 and continued with a single dose of diethylcarbamazine citrate (DEC), 6 mg/kg of body weight, plus albendazole annually over a period of 5-6 years. The GOI had set the target to achieve LF elimination by 2015 and now by 2030. The progress so far has been suboptimal. Much remains to be done as about 84 per cent of the total 328 endemic districts are still under MDA. The major challenge in implementing MDA is poor compliance. It is necessary to have a feasible alternative strategy addressing the above challenge to achieve the desired goal of LF elimination. At this juncture, a well-researched approach, i.e. the use of DEC-fortified salt, also advocated by the World Health Organization, as a unique form of MDA, is proposed. As per this strategy, a low dose of DEC (0.2% w/w) is added to the cooking salt at the manufacturing facility of iodized salt and consumed by the LF-endemic communities for about two years. Many examples of successful use of this strategy for LF elimination in small- and large-scale trials have been documented in India and several other endemic countries in the world. Implementing DEC-iodine-fortified salt is a safe, less expensive, more efficient and prompt approach for achieving the elimination of LF in India. Adverse effects are none or minor and self-limiting. The DEC-fortified salt strategy can easily piggyback on the existing countrywide deployment of iodized salt under the National Iodine Deficiency Disorders Control Programme (NIDDCP), which has achieved a great success in reducing iodine-deficiency disorders such as hypothyroidism. This existing robust programme can be leveraged to launch DEC-fortified salt for the community. If implemented appropriately, this strategy will ensure the complete cessation of LF transmission within two years from its introduction. If the said strategy is implemented in 2022, it is expected that India will be able to achieve the LF elimination by 2024, much before the global target of 2030.

Indexed as

Elephantiasis, FilarialFilaricidesIodineAlbendazoleDiethylcarbamazineHumansIndiaSodium Chloride, DietaryAlbendazoleDiethylcarbamazineFilaricidesIodineiodized saltSodium Chloride, DietaryDEC-fortified salteliminationIndialymphatic filariasisstrategy

Identifiers

PMID36124509
PMCPMC9707683
OpenAlexW4283777440

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.